Medicine & Life Sciences
plerixafor octahydrochloride
100%
Acute Myeloid Leukemia
77%
Hematopoietic Stem Cell Mobilization
66%
Hematopoietic Stem Cells
61%
Granulocyte Colony-Stimulating Factor
55%
Multiple Myeloma
53%
Integrin alpha4beta1
43%
T-Lymphocytes
38%
Stem Cells
38%
Bone Marrow
33%
Graft vs Host Disease
29%
Leukemia
28%
Erythrocytes
24%
Tissue Donors
21%
Neoplasms
21%
Transplants
20%
Suicide
20%
Immunotherapy
19%
Chimeric Antigen Receptors
17%
Azacitidine
16%
Drug Therapy
16%
Bortezomib
15%
((ENB-3-isopropoxy-PIDMP)Ga(III))
15%
Homologous Transplantation
15%
Thymidine Kinase
15%
Hematologic Neoplasms
14%
Therapeutics
14%
2-((1-(3,5-dichlorobenzenesulfonyl)pyrrolidine-2-carbonyl)amino)-4-(4-methyl-2-(methyl-(2-(4-(3-o-tolylureido)phenyl)acetyl)amino)pentanoylamino)butyric acid
14%
Peripheral Blood Stem Cells
13%
Recurrence
13%
Cytokine Release Syndrome
13%
Drug Resistance
13%
Hematopoietic Stem Cell Transplantation
13%
Survival
12%
Genes
12%
Myeloid Cells
12%
Bispecific Antibodies
12%
Integrins
11%
elotuzumab
11%
Immunoconjugates
11%
Phosphatidylserines
11%
Allogeneic Cells
10%
daratumumab
10%
SCID Mice
10%
Safety
10%
Haploidentical Transplantation
10%
Fetal Stem Cells
9%
Antibodies
9%
Cytarabine
9%
Blood Component Removal
9%
Chemical Compounds
Chemokine Receptor CXCR4 Antagonist
55%
Colony Stimulating Factor
28%
Donor
25%
Ganciclovir
16%
Positron
14%
Antagonist
14%
Refractory
14%
Molecule
13%
Protein
10%
Antigen
10%
Cytarabine
10%
Dose
10%
Sphingosine 1-Phosphate
10%
Route of Application
9%
Mitoxantrone
9%
Resistance
9%
Safety
9%
Etoposide
8%
Red
8%
Titanocene
8%
Radiopharmaceutical
7%
Bioluminescence
7%
Radionuclides
7%
Ablation
7%
Self-Association
7%
Thymidine
7%
Cell Death
6%
Asymmetry
6%
Pharmacokinetics
6%
Haematological
6%
Phospholipid
5%
Classifier
5%
Toxic
5%
Mutation
5%
Polypeptide
5%
Molecular Cluster
5%